ACXP
Acurx Pharmaceuticals, Inc.Company Information
- Company Name
- Acurx Pharmaceuticals, Inc.
- CIK
- CIK0001736243
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- ACXP: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ACXP
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-01-06
- Last sale
- —
- Shares purchased (TTM)
- 167,488
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 163,206
- Shares outstanding
- 2,718,433
- Ownership
- 6.00%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -4.05%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash | 11 | 9 | 8 | 6 | 6 | 5 | 4 | 6 | 6 | 9 | 7 | 7 | ||||||
| Accounts And Other Receivables Net Current | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | - | 0 | - | ||||||
| Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | - | - | - | - | 6 | 5 | - | 6 | - | - | - | 7 | ||||||
| Assets | 11 | 10 | 8 | 6 | - | - | 4 | - | 7 | 9 | 8 | - | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 3 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Liabilities Current | 3 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Liabilities | 3 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 87 | 84 | 81 | 77 | 75 | 72 | 68 | 67 | 65 | 64 | 58 | 52 | ||||||
| Retained Earnings Accumulated Deficit | -79 | -77 | -75 | -74 | -72 | -69 | -67 | -65 | -62 | -58 | -53 | -48 | ||||||
| Stockholders Equity | 8 | 7 | 5 | 4 | 4 | 2 | 1 | 3 | 3 | 6 | 5 | 4 | ||||||
| Liabilities And Stockholders Equity | 11 | 10 | 8 | 6 | 6 | 5 | 4 | 6 | 7 | 9 | 8 | 7 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | - | - | - | - | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | - | - | - | 10 | - | - | - | - | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 5 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 5 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAcurx Pharmaceuticals, Inc. (ACXP) — SEC Financial Statements & Analysis
Acurx Pharmaceuticals, Inc. (ACXP) is a pharmaceutical preparations company, incorporated in DE. Acurx Pharmaceuticals, Inc. trades on Nasdaq as: ACXP. Acurx Pharmaceuticals, Inc. (ACXP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Acurx Pharmaceuticals, Inc. carries a market cap of $6.60M, a P/E ratio of -0.88x, a P/B ratio of 0.81x, an enterprise value of $-4.05M, and an EV/EBITDA multiple of 0.53x. On profitability, it posts a Return on Equity (ROE) of -128.11% and a Return on Assets (ROA) of -162.38%. Per share, it reports EPS of $-1.76, diluted EPS of $-1.76, free cash flow per share of $-1.45, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -24.93% year-over-year and EPS growth of -79.02% year-over-year. On the balance sheet, it maintains a current ratio of 2.38x, a quick ratio of 2.36x, working capital of $3.57M, a debt-to-equity ratio of 0.35x, a debt ratio of 0.42, free cash flow of $-6.18M (TTM), and net debt of $-10.66M. Figures sourced from SEC EDGAR.
- Market Cap
- $6.60M
- P/E TTM
- -0.88x
- EPS TTM
- $-1.76
- P/B TTM
- 0.81x
- ROE TTM
- -128.11%
- ROA TTM
- -162.38%
- Debt To Equity
- 0.35x
- Free Cash Flow TTM
- $-6.18M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Acurx Pharmaceuticals, Inc. in?
Acurx Pharmaceuticals, Inc. (ACXP) operates in the Pharmaceutical Preparations industry.
What exchange does ACXP trade on?
Acurx Pharmaceuticals, Inc. (ACXP) trades on the Nasdaq.
Where is Acurx Pharmaceuticals, Inc. incorporated?
Acurx Pharmaceuticals, Inc. is incorporated in DE.
When was Acurx Pharmaceuticals, Inc. (ACXP)'s most recent SEC filing?
Acurx Pharmaceuticals, Inc. (ACXP)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is ACXP's market cap?
Acurx Pharmaceuticals, Inc. (ACXP) has a market capitalization of $6.60M as of 2026-06-30.
What is ACXP's EPS (earnings per share)?
Acurx Pharmaceuticals, Inc. (ACXP)'s trailing twelve month EPS is $-1.76 as of 2026-06-30.
What is ACXP's ROE (return on equity)?
Acurx Pharmaceuticals, Inc. (ACXP)'s trailing twelve month Return on Equity (ROE) is -128.11% as of 2026-06-30.
What is ACXP's ROA (return on assets)?
Acurx Pharmaceuticals, Inc. (ACXP)'s trailing twelve month Return on Assets (ROA) is -162.38% as of 2025-06-30.
What is ACXP's EV/EBITDA?
Acurx Pharmaceuticals, Inc. (ACXP)'s trailing twelve month EV/EBITDA is 0.53x as of 2026-06-30.